Cantor Fitzgerald begins coverage of five in ‘GovTech’ with three buys
As previously reported last night, Cantor Fitzgerald analyst Colin Canfield initiated coverage of five Government Technology & Space, or ...
Cantor Fitzgerald raises Fortinet stock target to $115
Cantor Fitzgerald adjusted its price target for Fortinet shares (NASDAQ:FTNT) to $115.00, an increase from the previous target of $110.00. The firm maintained a Neutral stance on the cybersecurity ...
Cantor Fitzgerald Keeps Their Buy Rating on Pinterest (PINS)
Cantor Fitzgerald analyst Deepak Mathivanan maintained a Buy rating on Pinterest (PINS – Research Report) today and set a price target of ...
Cantor Fitzgerald lifts Pinterest stock price target to $48
Cantor Fitzgerald increased the price target for Pinterest Inc (NYSE:PINS) shares, setting a new goal of $48.00, up from the previous target of $36.00. The firm maintained its Overweight rating on the ...
Rejuvenation of a Sharp Employer Non-Compete Tool: Delaware Supreme Court Reinvigorates the Employee Choice Doctrine
The authors write "Post-employment restrictive covenants, once viewed as near fortresses to protect proprietary information, ...
Trump Taps McKinsey CLO Pierre Gentin for Commerce Department GC
President Trump has nominated Pierre Gentin, chief legal officer of the consulting giant McKinsey & Co. since 2019, to serve ...
Vanda Pharmaceuticals And Anaptys Announce Exclusive Global License Agreement For Vanda To Develop And Commercialize Imsidolimab, An IL-36R Antagonist
Imsidolimab inhibits the function of the IL-36R, compensating for the deficiency of the endogenous IL-36 regulator in patients with GPP. Imsidolimab has successfully concluded its development program ...